Illumina (NASDAQ:ILMN) Upgraded by Sanford C. Bernstein to Hold Rating

Sanford C. Bernstein upgraded shares of Illumina (NASDAQ:ILMN) to a hold rating in a research report sent to investors on Thursday,Zacks.com reports.

Several other research analysts also recently commented on the company. Royal Bank Of Canada started coverage on Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price for the company. Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Citigroup lifted their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Canaccord Genuity Group dropped their target price on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a report on Friday, May 1st. Finally, Wall Street Zen lowered Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $146.00.

Illumina Stock Down 0.6%

Shares of ILMN stock opened at $176.55 on Thursday. Illumina has a 12-month low of $88.00 and a 12-month high of $182.84. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The firm has a fifty day moving average of $149.62 and a 200-day moving average of $137.66. The company has a market capitalization of $26.71 billion, a price-to-earnings ratio of 32.10, a P/E/G ratio of 3.32 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business earned $0.97 EPS. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts predict that Illumina will post 5.21 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In other news, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the transaction, the director directly owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the sale, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Illumina

Hedge funds and other institutional investors have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB increased its holdings in Illumina by 7.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after acquiring an additional 79 shares during the period. HighPoint Advisor Group LLC increased its holdings in shares of Illumina by 3.7% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares during the period. Meeder Advisory Services Inc. increased its holdings in shares of Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after purchasing an additional 85 shares during the period. Toronto Dominion Bank raised its position in shares of Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after buying an additional 92 shares in the last quarter. Finally, Panagora Asset Management Inc. boosted its stake in Illumina by 3.9% during the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after buying an additional 96 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.